Pyrazolonaphthyridine Derivative for Selective PDE IV Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE IV inhibitors face challenges such as non-selectivity, side effects like nausea, and interactions with drug metabolizing enzymes, limiting their clinical application for asthma and COPD treatment.
Innovation Solution
A novel heterocycle compound with a specific pyrazolonaphthyridine derivative structure, featuring halogenated alkyl or alkoxy groups, is developed to enhance PDE IV inhibitory activity while minimizing side effects and drug metabolizing enzyme inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If theophylline is used as a PDE inhibitor, then bronchodilator action is achieved, but isozyme non-selectivity causes unwanted actions on the heart and central nervous system
Solution Approach 1:
The patent applies local quality by designing a pyrazolonaphthyridine derivative structure with specific substituents (halogenated alkyl or alkoxy groups at positions 3 and 5) that targets PDE IV selectively in airway smooth muscle and inflammatory cells, while avoiding non-specific inhibition of other PDE isozymes in the heart and central nervous system. This localized specificity resolves the contradiction between achieving bronchodilator action and avoiding systemic side effects.
2Reliability
If rolipram is used as a PDE IV selective inhibitor, then PDE IV selectivity is achieved, but central nervous system penetration causes emetic action
Solution Approach 1:
The patent modifies the naphthyridine core structure with specific halogenated substituents to achieve PDE IV selectivity while controlling molecular properties to prevent central nervous system penetration. The halogenated alkyl or alkoxy groups at positions 3 and 5 provide both enzymatic selectivity and appropriate pharmacokinetic properties, resolving the contradiction between PDE IV selectivity and avoidance of central side effects.
Solution Approach 2:
The patent changes molecular parameters by introducing halogenated alkyl or alkoxy groups with specific chain lengths (C1-C6) and configurations. These parameter changes optimize the balance between PDE IV binding affinity and blood-brain barrier penetration, achieving selectivity without central nervous system side effects.
3Reliability
If conventional PDE IV inhibitors are used, then antasthmatic effect is achieved, but inhibition of drug metabolizing enzymes causes various side effects
Solution Approach 1:
The patent designs the pyrazolonaphthyridine derivative with specific halogenated substituents that provide high PDE IV inhibitory activity while avoiding interaction with drug metabolizing enzymes. The localized structural features target the PDE IV active site specifically, preventing off-target inhibition of metabolic enzymes and resolving the contradiction between antasthmatic efficacy and metabolic safety.
Data Source
AI summary
The compound of the present invention is a novel compound which has a specific heterocycle skeleton, particularly a pyrazolonaphthyridine or pyrazoloquinoline skeleton having an organic group (e.g., a carbocycle and a heterocycle) bonding through an alkylene group at 3-position and a carbocycle bonding at 5-position and has a phosphodiesterase IV inhibitory activity. At least one of the ring (the carbocycle or the heterocycle) bonding at 3-position of the pyrazolonaphthyridine skeleton and the carbocycle bonding at 5-position may have a halogenated alkyl group and/or a halogenated alkoxy group as a substituent. Such a compound or a salt thereof is useful as a phosphodiesterase IV inhibitor and the like. According to the present invention, a novel compound having a high phosphodiesterase IV inhibitory effect can be provided.